ArticleMedicine2026
Circulating cytokines mediate the risk of COPD: A mediation analysis based on 473 gut microbiota and 91 circulating cytokines.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In recent years, the roles of gut microbiota and circulating cytokines in chronic obstructive pulmonary disease (COPD) have gradually attracted attention. However, it remains unclear whether cytokines act as mediators from gut microbiota to COPD. This study utilized the mediation Mendelian randomization analysis method to explore the potential causal effects of gut microbiota and cytokines on COPD and reveal the potential mechanistic connections between them. We aggregated data from large-scale genome-wide association studies. Inverse variance weighted was used as the primary statistical method, and a series of sensitivity analyses were conducted to test the reliability of the Mendelian randomization results. We identified 24 gut microbiota species that show robust associations with COPD risk, with results supported by sensitivity analyses. Specifically, 11 gut microbiota species may increase the risk of COPD, while the remaining 13 species have a protective effect. Additionally, we observed associations between 7 circulating cytokines and COPD risk, among which 6 may increase the disease risk and 1 may reduce the disease risk. Mediation analysis revealed the complex regulatory roles of 4 key cytokines (LIF, IL-1A, CXCL10, CD6) between gut microbiota and COPD. This study reveals that circulating cytokines can act as potential mediators between gut microbiota and COPD. These findings not only deepen our understanding of the pathophysiological mechanisms of COPD but also provide new perspectives for the early intervention and treatment of COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.